Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC).
Lustberg M, Miller B, Wu Y, Xue W, Deighan C, Carothers S, Berger M, Shapiro C, Chalmers J. Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 172-172. DOI: 10.1200/jco.2012.30.27_suppl.172.Peer-Reviewed Original ResearchBlood samplesBreast cancerLeukocyte populationsPeripheral blood leukocyte populationsNegative depletionAdvanced breast cancerMultiparameter flow cytometry analysisVenous blood samplesBlood leukocyte populationsPrimary breast tumorsMacrophages/monocytesProgression of diseaseBreast tumor stromaCell surface markersAdditional phenotypic characterizationFlow cytometry analysisPositive leukocytesBC patientsPeripheral bloodPredictive markerPoor responseCD 68Such tumorsPatient's stageT cellsAssessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy
Garcia-Villa A, Balasubramanian P, Miller B, Lustberg M, Ramaswamy B, Chalmers J. Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Frontiers In Oncology 2012, 2: 128. PMID: 23112954, PMCID: PMC3480704, DOI: 10.3389/fonc.2012.00128.Peer-Reviewed Original ResearchStage IV breast cancerTumor cellsBreast cancer patientsPlatinum-based therapySolid tumor malignanciesPotential of CTCsSurface markers CD45Γ-H2AXDNA-damaging therapiesΓ-H2AX levelsPlatinum therapyPeripheral bloodCancer patientsPredictive markerPatient outcomesPrognostic markerBreast cancerΓ-H2AX stainingPatient's conditionTumor malignancyTherapyNegative depletionLiquid biopsyStaining patternCell apoptosis